Cover Image
Market Research Report

Analyzing Generics Market in France 2017

Published by Aruvian's R'search Product code 549079
Published Content info 95 Pages
Delivery time: 1-2 business days
Price
Back to Top
Analyzing Generics Market in France 2017
Published: August 1, 2017 Content info: 95 Pages
Description

The French generic drugs industry has been growing quite well in recent years. While sales of generic drugs took a hit in 2014 as the market was impacted by price cuts, the launch of new generic drugs following many branded drugs going off patents prevented the market from deteriorating too much. The French government has plans to grow the generics market further in the coming years and are putting in place regulations to boost the growth of the industry.

In 2016, the French generics industry crossed revenues of nearly USD 4 billion and it is expected that the industry will continue to grow comfortably to reach a value of USD 5.5 billion by the end of 2021.

Aruvian Research presents Analyzing Generics Market in France 2017 - a comprehensive coverage of the French generic drugs market. Beginning with a sectional description on the global generic industry, the report looks at an overview of the industry, an analysis of the market volume and value, industry segmentation and an industry forecast.

Moving on, we analyze the Generics Industry in Europe through the same parameters.

The Generics Industry in France is analyzed through an industry overview which spans the data from 2012 till 2021. An analysis of the industry's value and volume data is included along with an industry segmentation by geography. Industry forecast of the industry is also included.

We also include a Porter's Five Forces analysis of the French Generics Industry. Generics pricing and reimbursement situation in France and trends and challenges facing the industry are analyzed.

Analysis of the major industry players in the French generics market are analyzed through an analysis of their business segments, a financial analysis and a SWOT analysis. Players analyzed include Sanofi SA, Les Laboratoires Servier, Teva Pharmaceutical Industries and others.

This research report helps you get an insider's look at the French generic industry and helps you understand what the future holds for the industry. Regulatory framework, pricing and reimbursement scenarios, comparison of the French market with its regional counterparts, all these data points makes this report an essential resource for analytical purposes.

Table of Contents

Table of Contents

A. Executive Summary

B. Analyzing the Global Generics Industry

  • B.1. Industry Definition
  • B.2. Industry Overview
  • B.3. Industry Value & Volume Analysis
  • B.4. Industry Segmentation by Geography
  • B.5. Patent Expiries
  • B.6. Global Generic Industry Structure
  • B.7. Industry Forecast

C. Generics Industry in Europe

  • C.1. Industry Overview
  • C.2. Industry Value & Volume
  • C.3. Industry Segmentation by Geography
  • C.4. Industry Forecast

D. Generics Industry in France

  • D.1. Industry Overview
  • D.2. Industry Value & Volume
  • D.3. Industry Segmentation by Geography
  • D.4. Industry Forecast

E. Generics Industry in France: Porter's Five Forces Strategy Analysis

  • E.1. Introduction
  • E.2. Bargaining Power of Buyers
  • E.3. Bargaining Power of Suppliers
  • E.4. Competitive Rivalry in the Industry
  • E.5. Threat of New Entrants
  • E.6. Threat of Substitutes

F. Pricing & Reimbursement in France

  • F.1. Overview
  • F.2. Generics Pricing & Reimbursement Scenario
  • F.3. Trends & Challenges

G. Major Industry Players

  • G.1. Allergan Plc
    • G.1.1. Corporate Analysis
    • G.1.2. Financial Analysis
    • G.1.3. SWOT Analysis
  • G.2. Les Laboratoires Servier
    • G.2.1. Corporate Analysis
    • G.1.2. Financial Analysis
    • G.1.3. SWOT Analysis
  • G.3. Mylan N.V.
    • G.3.1. Corporate Analysis
    • G.3.2. Financial Analysis
    • G.3.3. SWOT Analysis
  • G.4. Sanofi SA
    • G.4.1. Corporate Analysis
    • G.4.2. Financial Analysis
    • G.4.3. SWOT Analysis
  • G.5. Teva Pharmaceutical Industries Limited
    • G.5.1. Corporate Analysis
    • G.5.2. Financial Analysis
    • G.5.3. SWOT Analysis
  • G.6. Sandoz International GmbH

H. Glossary of Terms

List of Figures

  • Figure 1: Historical Revenues of Leading Generic Companies (in USD Million), 2008-2009
  • Figure 2: Growth of the Global Generics Industry by Value (in USD Billion), 2012-2016
  • Figure 3: Generics Percentage of Total Pharmaceutical Volume & Market Volume of Global Generics Industry (%), 2012-2016
  • Figure 4: Global Generics Market Segmentation by Geography (%), 2016
  • Figure 5: Revenues of Top 10 Drugs that went off Patent between 2010-2014 (in USD Million)
  • Figure 6: Market Share of Leading Generic Companies Worldwide (%), 2016
  • Figure 7: Comparison of Revenues of Leading Generic Companies (in USD Million), 2013-2014
  • Figure 8: Global Generics Industry Forecast (in USD Billion), 2016-2021
  • Figure 9: Global Generics Industry Forecast by Volume (% of Pharma Volume), 2016-2021
  • Figure 10: Value of the European Generics Market (in USD Billion), 2012-2016
  • Figure 11: Volume Growth of the European Generics Market (%), 2012-2016
  • Figure 12: Share of the European Generics Industry by Countries (%), 2016
  • Figure 13: Forecast of the European Generics Market (in USD Billion), 2016-2021
  • Figure 14: Volume Forecast of the European Generics Market (%), 2016-2021
  • Figure 15: Value of the Generics Market in France (in USD Billion), 2012-2016
  • Figure 16: Volume Growth of the Generics Market in France (%), 2012-2016
  • Figure 17: Share of France in the European Generics Industry (%), 2016
  • Figure 18: Forecast of the Generics Market in France (in USD Billion), 2016-2021
  • Figure 19: Volume Forecast of the Generics Market in France (%), 2016-2021
  • Figure 20: Porter's Five Forces Strategy Analysis of the Generics Industry in France
  • Figure 21: Bargaining Power of Buyers in the French Generics Industry
  • Figure 22: Bargaining Power of Suppliers in the French Generics Industry
  • Figure 23: Competitive Rivalry in the French Generics Industry
  • Figure 24: Threat of New Entrants to the French Generics Industry
  • Figure 25: Threat of Substitutes to the French Generics Industry
  • Figure 26: Financing Law of Social Security (Loi de Financement de la Sécurité Sociale) in France
  • Figure 27: Revenues & Profitability of Allergan Plc (in USD Million), 2011-2015
  • Figure 28: Revenues & Profitability of Sanofi SA (in USD Million), 2011-2015

List of Tables

  • Table 1: Growth of the Global Generics Industry by Value (in USD Billion), 2012-2016
  • Table 2: Generics Percentage of Total Pharmaceutical Volume & Market Volume of Global Generics Industry (%), 2012-2016
  • Table 3: Global Generics Industry, Segmentation by Geography (in USD Billion), 2016
  • Table 4: Global Generics Industry Forecast (in USD Billion), 2016-2021
  • Table 5: Global Generics Industry Forecast by Volume & Percentage Growth (% of Pharma Volume), 2016-2021
  • Table 6: Value of the European Generics Market (in USD Billion), 2012-2016
  • Table 7: Volume Growth of the European Generics Market (%), 2012-2016
  • Table 8: Share of the European Generics Industry by Countries (% & USD Billion), 2016
  • Table 9: Forecast of the European Generics Market (in USD Billion), 2016-2021
  • Table 10: Volume Forecast of the European Generics Market (%), 2016-2021
  • Table 11: Value of the Generics Market in France (in USD Billion), 2012-2016
  • Table 12: Volume Growth of the Generics Market in France (%), 2012-2016
  • Table 13: Share of France in the European Generics Industry (% & USD Billion), 2016
  • Table 14: Forecast of the Generics Market in France (in USD Billion), 2016-2021
  • Table 15: Volume Forecast of the Generics Market in France (%), 2016-2021
  • Table 16: Key Financials of Allergan Plc (in USD Million), 2011-2015
  • Table 17: Key Financials of Sanofi SA (in USD Million), 2011-2015
  • Table 18: Key Financials of Teva Pharmaceutical (in USD Million), 2011-2015
  • Table 19: Revenues & Profitability of Teva Pharmaceutical (in USD Million), 2011-2015
Back to Top